{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-011766","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.367969+00:00","generated_at":"2026-06-05T02:47:32.570534+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BridgeBio prices $250M public offering at $29.00/share; funds acoramidis launch and pipeline","bullets":["8,620,690 shares priced at $29.00; underwriters have 30-day option for 1,293,103 additional shares.","Net proceeds estimated at ~$250M; expected to fund operations into H2 2026.","Proceeds to support commercial launch of acoramidis, if approved, and clinical/preclinical development.","Offering expected to close March 8, 2024; 60-day lock-up for directors and officers.","J.P. Morgan, Cantor Fitzgerald, Mizuho act as joint book-running managers."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-011766","json":"https://secwatch.observer/filing/0001140361-24-011766.json","markdown":"https://secwatch.observer/filing/0001140361-24-011766.md","text":"https://secwatch.observer/filing/0001140361-24-011766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124011766/0001140361-24-011766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124011766/ny20019103x3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:47:32.570534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6630777ba796e4c374ff801bfff42c2b240d7c0","claim":"BridgeBio Pharma, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters valued at approximately $250.0 million (effective 2024-03-05).","evidence_excerpt":"On March 5, 2024, BridgeBio Pharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 8,620,690 shares of the Company's common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $29.00 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124011766/0001140361-24-011766-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters"},{"label":"Value","value":"approximately $250.0 million"},{"label":"Effective","value":"2024-03-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}